← Leaderboards
Pinku Mukherjee
Mayo Clinic Coll Of Medicine, Rochester
$4,770,733
Attributed
$5,301,027
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $688.3K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,301,027 · 9
By mechanism
P50$2,158,851 · 1
R01$1,318,851 · 1
R41$1,243,049 · 4
R15$434,003 · 1
R03$146,273 · 1
P20$0 · 1
Top collaborators
- Ru Zhou3 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Charles David James$11,072,867
- Ping Yang$15,335,745
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant Neoplasm Of PancreasPancreatic Ductal AdenocarcinomaDesignMalignant NeoplasmsMouse ModelBaseClinicImmuneMucin-1 Staining MethodExpectationAutoantigensImmune TargetingCodon NucleotidesTherapeutic InterventionAntibodiesNeoplasm MetastasisCessation Of LifeGlycoproteinsResistanceOverexpressionResponseMucinsCells
Grant awards (20)
Optimized targeted radiotherapy of pancreatic cancer$400,000
R41 · FY2025 · CA · contact PI
An integrated strategy using a serum and imaging biomarker for the early detection of pancreatic cancer.$400,000
R41 · FY2021 · CA · contact PI
The use of tMUC1/CD3 bispecific antibody to control pancreatic ductal adenocarcinoma$260,588
R41 · FY2021 · CA · contact PI
Novel immunotherapy strategy for treatment of pancreatic cancer$182,461
R41 · FY2016 · CA · contact PI
MUC1 regulation of TGF-beta function in pancreatic cancer cells$72,023
R03 · FY2014 · CA · contact PI
MUC1 enhances Neuropilin-1 signaling in pancreatic ductal adenocarcinoma$434,003
R15 · FY2013 · CA · contact PI
P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site$128,024
P50 · FY2013 · CA · contact PI
MUC1 regulation of TGF-beta function in pancreatic cancer cells$74,250
R03 · FY2013 · CA · contact PI
P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site$431,346
P50 · FY2012 · CA · contact PI
P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site$417,285
P50 · FY2011 · CA · contact PI
P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site$438,466
P50 · FY2010 · CA · contact PI
Role of MUC1 in Pancreatic Cancer$248,188
R01 · FY2010 · CA · contact PI
P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site$440,146
P50 · FY2009 · CA · contact PI
Role of MUC1 in Pancreatic Cancer$248,188
R01 · FY2009 · CA · contact PI
P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site$303,584
P50 · FY2008 · CA · contact PI
Role of MUC1 in Pancreatic Cancer$214,596
R01 · FY2008 · CA · contact PI
Role of MUC1 in Pancreatic Cancer$56,860
R01 · FY2008 · CA · contact PI
Role of MUC1 in Pancreatic Cancer$271,456
R01 · FY2007 · CA · contact PI
Role of MUC1 in Pancreatic Cancer$279,563
R01 · FY2006 · CA · contact PI
Potent combinational treatment for pancreatic cancer$0
P20 · FY2003 · CA